Parabilis Shares Slip Below Ra Capital's Buy Zone
Ra Capital accumulated Parabilis shares at $27-$30 per share in July, but the company's 772% EPS miss has left the cost basis underwater. The stock trades below the institutional buyer's entry price,
Parabilis Shares Slip Below Ra Capital's Buy Zone
NEW YORK, October 14 —
Ra Capital Management spent $6.92 million accumulating Parabilis Medicines, Inc. (PBLS) shares in six open-market transactions over three days in July 2026, every one of them executed above current prices, a cost basis that now sits underwater after the company reported a Q2 EPS miss of 772.6% against Wall Street's consensus.
- Q2 2026 EPS of -$2.12 against consensus of -$0.24, a miss of 772.6%, on zero trailing revenue. [SEC 8-K]
- Ra Capital's six July purchases ranged from $27.13 to $30.00 per share; PBLS now trades at $26.85.
- $1.12 billion cash, $0.05 billion debt; market cap approximately $3.32 billion.
The Largest Biotech IPO Meets Its First Earnings Test
Parabilis Medicines, which develops helical peptide therapeutics targeting proteins considered undruggable through its proprietary Helicon platform, completed what Sixty Degree Capital called the largest biotech IPO in history at $770 million in 2026. That history-making debut has since collided with clinical-stage arithmetic: the company carries no approved products and zero trailing revenue, so any earnings figure is a pure cash-burn number. A -$9.51 trailing EPS and -$111 million in operating cash flow were always part of the deal. What was not priced in, apparently, was a quarterly EPS figure that landed more than eight times worse than consensus, a divergence suggesting the burn rate accelerated faster than analysts had modeled.
Ra Capital's Cost Basis Is Now the Trade's Benchmark
Between July 20 and July 22, Ra Capital executed six purchases at prices from $27.13 to $30.00, with the largest single block, 98,433 shares at $27.13, filed on July 20. The purchases followed the IPO by weeks, positioning Ra Capital as an accumulator on the open market after anchoring the offering itself. With PBLS at $26.85, every transaction is now marginally underwater. The stock shed 9% in a single session approximately five trading days before this writing, per Quiver Quantitative, then recovered 7% in the most recent session per MarketBeat, short-term volatility that leaves Ra Capital's blended cost basis still above the current price. Institutional ownership at 82.4% of shares outstanding means the float is concentrated; short interest at 6.8% is significant but not yet a dominant force.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| PBLS | $3.3B | n/a | -15.0% |
| KLRA | $1.4B | n/a | -58.6% |
| COAG | $1.4B | n/a | -12.4% |
| EIKN | $364M | n/a | -55.2% |
| MANE | $4.9B | n/a | +208.0% |
| GENB | $1.6B | n/a | -3.1% |
What Resolves the Setup
The $1.12 billion cash position against $0.05 billion in debt gives Parabilis a long runway, the balance sheet does not force a near-term resolution. FOG-001, the company's lead TCF-blocking beta-catenin inhibitor, is the binary catalyst that eventually will. Analyst consensus puts PBLS at $41.75, a 55% premium to today's price; that gap reflects clinical optionality, not operating performance. The number that would vindicate or undermine Ra Capital's conviction is a FOG-001 data readout: a clean efficacy signal closes the gap to the analyst target, while a setback would pressure a stock that already trades below its primary institutional buyer's cost basis. Run the free Parabilis Medicines, Inc. deep-dive →
Current fundamentals, valuation and filing history for Parabilis Medicines, Inc. (PBLS) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why are Parabilis shares down?
Parabilis reported Q2 2026 EPS of -$2.12 against Wall Street consensus of -$0.24, a miss of 772.6%. As a clinical-stage company with zero trailing revenue and no approved products, any EPS figure is purely a cash-burn number. The magnitude of the miss suggests the burn rate accelerated faster than analysts had projected.
Did Ra Capital lose money on Parabilis?
Ra Capital's six July purchases ranged from $27.13 to $30.00 per share, with PBLS now trading at $26.85. Every transaction is now marginally underwater, leaving the cost basis above the current price. However, the company's $1.12 billion cash position gives it a long runway without forcing a near-term resolution.
What is FOG-001?
FOG-001 is Parabilis's lead drug candidate, a TCF-blocking beta-catenin inhibitor targeting proteins considered undruggable through the company's proprietary Helicon platform. A clean efficacy signal from this asset could close the gap to the $41.75 analyst price target, while a setback would further pressure the stock.
What's the Parabilis analyst price target?
Analyst consensus puts PBLS at $41.75 per share, a 55% premium to the current trading price of $26.85. This gap reflects clinical optionality, not current operating performance, meaning the analyst view depends entirely on FOG-001 success.
Why was the Parabilis IPO significant?
Parabilis completed what Sixty Degree Capital called the largest biotech IPO in history at $770 million in 2026. The company develops helical peptide therapeutics using its proprietary Helicon platform and has no approved products yet.
Parabilis Medicines' largest institutional backer, Ra Capital Management, spent $6.92 million accumulating PBLS shares at $27.13–$30.00 in July 2026, just months after anchoring the company's record-setting IPO. The stock now trades at $26.85—below every one of those open-market purchases—having shed as much as 9% in a single session last week before recovering 7% in the most recent session.